Mylan NV’s latest troubles could not come at a worse time.
Two years ago, Mylan was a swaggering drugmaker on the way up, buying up rivals as it grew and diversified.
Then it faced political scrutiny over price hikes for its EpiPen allergy shot and increasing pressure on prices for the generic drugs that are the company’s backbone.
In August, Mylan cut its outlook for next year, and on Tuesday came another blow: Its No. 2 executive was one of the first two top managers accused in an industry-wide civil investigation of colluding in a “sinister” conspiracy to prop up prices.
After reaching an all-time high of US$76.06 in April 2015, its shares have been cut in half and closed on Tuesday at US$35.71, dropping 6.6 percent for the day.
Like other drugmakers, Mylan has been under increasing pressure from regulators at the US Food and Drug Administration (FDA) over the past year.
Taking up US President Donald Trump’s call to reduce drug prices, the FDA has said it will accelerate the approval of copycat drugs that will push prices down further. The agency has said it will specifically target drugs that only have a few generic competitors, trimming the industry’s already thin margins further.
The multi-year civil case against Mylan and 17 other makers of generic pills — with a dragnet that could wrap in other senior drug executives around the industry — could prove damaging.
Not only does it target Mylan president Rajiv Malik, but the alleged conduct in the complaint supposedly helped generic-drug makers preserve their margins and markets, avoiding some of the competition that has already been pressuring the industry.
In their 243-page complaint, 45 US states and Washington said that more than a dozen drugmakers worked together to share the market and avoid a “fight to the bottom.”
At industry conferences, over dinner parties and hundreds of telephone calls, e-mails and text messages, executives would agree to raise or maintain prices for specific drugs in tandem or delineate each company’s market share.
Malik is one of two senior drug executives named in the new complaint, in which the states are seeking to expand an earlier lawsuit alleging price and market fixing.
Mylan, which is also named as a defendant in the case, said it stands behind Malik and will “defend this case vigorously.”
Malik’s lawyer, Robert Cleary of Proskauer Rose LLP, said in a telephone interview that the executive “emphatically and categorically denies the allegations in the complaint” and “is confident he will be completely vindicated.”
The complaint details numerous telephone calls and e-mails between Malik and executives at closely held Indian drugmaker Emcure Pharmaceuticals Ltd and its subsidiary, Heritage Pharmaceuticals, around the time when Heritage launched an antibiotic called Doxy DR.
Mylan — then the only other generic maker with that pill on the market — agreed to give up two large accounts to Heritage, helping Heritage enter the market without putting pressure on prices, the filling said.
“Given direct involvement of executives in this case and the evidence we had implicating them, we felt as a group of antitrust enforcers that it was important to hold these individuals accountable,” Connecticut Assistant Attorney General Joseph Nielsen said on Tuesday on a conference call with reporters.
The civil investigation has run parallel to a criminal probe by the US Department of Justice that has so far led to guilty pleas from two former executives of Heritage, the Emcure subsidiary. The complaint has now expanded from six to 18 companies and 15 drugs.
Malik has worked at Mylan since 2007 and became president in 2012. Previously, he worked at Sandoz and at Ranbaxy Laboratories Ltd. One of Mylan’s senior-most executives, he is a regular speaker on quarterly earnings calls.
The company, which has a legal address in the Netherlands and is run from Canonsburg, Pennsylvania, describes him on its Web site as the leader of “all global commercial and operational activities.”
“Rajiv is easily one of the foremost generic heads out there and is a core part of Mylan leadership,” Evercore-ISI analyst Umer Raffat said.
The troubles might not end at Mylan and Emcure. On the conference call on Tuesday, Connecticut Attorney General George Jepsen suggested that other executives could be drawn in.
“Every time we kick a door in we make new discoveries,” Jepsen told reporters.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the